biliary atresia
Conditions
Interventions
Short-term Group:Cefoperazone 5 days
Long-term Group:Cefoperazone 14 days
Sponsors
Children's Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: 1. Perform Kasai portoenterostomy for Type 3 Biliary Atresia in Children's Hospital of Fudan University; 2. Post-conception age older than 36 weeks, both genders; 3. No history of drug allergies to the medications used during the trial; 4. No preoperation use of antibiotics or probiotics; 5. Written informed consent to participate in the clinical trial obtained prior to completion of Kasai procedure.
Exclusion criteria
Exclusion criteria: 1. Kasai portoenterostomy performed in other institutions; 2. Known allergy to the medication used during the trial or other adjuvant therapies; 3. Preoperation use of antibiotics or probiotics; 4. With other severe concurrent illnesses that will interfere with the conduct and results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of cholangitis at 6 months after Kasai procedure; | — |
Secondary
| Measure | Time frame |
|---|---|
| The first occurrence, frequency and duration of cholangitis;Survival with native liver at 6 months after Kasai procedure;Serum total bilirubin concentration and liver function prior and at 1 month, 3 months, 6 months after Kasai procedure;Percentage of cholangitis at 3 months after Kasai procedure;Percentage of jaundice clearance (serum total bilirubin less than 20 umol/L) at 3 months, 6 months after Kasai procedure;Percentage of adverse events at 1, 3, 6 months after Kasai procedure; | — |
Countries
China
Contacts
Public ContactShan Zheng
Children's Hospital of Fudan University
Outcome results
None listed